Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verrica Pharmaceuticals Inc VRCA

Healthcare
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential... see more

Recent & Breaking News (NDAQ:VRCA)

Verrica Announces Pricing of $42.0 Million Public Offering

GlobeNewswire 15 hours ago

Verrica Announces Proposed Public Offering

GlobeNewswire 1 day ago

Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition

GlobeNewswire November 4, 2024

Verrica Pharmaceuticals Inc. Investor Alert (NASDAQ: VRCA): Schubert Jonckheer & Kolbe LLP Investigating Potential Shareholder Claims Against the Company's Officers and Directors for Possible False Statements

PR Newswire October 30, 2024

Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference

GlobeNewswire October 24, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Business Wire October 11, 2024

Grabar Law Office Continues to Investigate Claims on Behalf of Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA)

Newsfile October 8, 2024

Attention Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): a Securities Fraud Class Action Has Survived a Motion to Dismiss

Newsfile October 4, 2024

Verrica Pharmaceuticals Announces Restructuring of Commercial Organization

GlobeNewswire October 2, 2024

Attention Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): a Securities Fraud Class Action Has Survived a Motion to Dismiss

Newsfile September 30, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

PR Newswire September 27, 2024

Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA): Grabar Law Office Investigates Claims on Your Behalf

Newsfile September 26, 2024

Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA)

Newsfile September 20, 2024

VERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA

Business Wire September 13, 2024

Grabar Law Office Investigates Claims on Behalf of Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) After Securities Fraud Class Action Survives Motion to Dismiss

Newsfile September 5, 2024

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York

GlobeNewswire September 4, 2024

Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results

GlobeNewswire August 14, 2024

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

GlobeNewswire August 14, 2024

Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024

GlobeNewswire August 6, 2024

Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.

GlobeNewswire July 1, 2024